Literature DB >> 31030057

Cannabis use in Europe: Current trends and public health concerns.

Jakob Manthey1.   

Abstract

In this contribution, I summarize recent trends of cannabis use in Europe and their public health implications. The first trend refers to an increase of treatment demand for cannabis problems by 76% while prevalence of cannabis use remained largely stable in the same period, based on available data. There are good reasons to assume that this trend reflects increases in the prevalence of cannabis use disorders, however, data to support this claim are not available. Potential drivers for a rising prevalence of cannabis use disorders comprise changes in consumption patterns and increasing levels of THC in available cannabis products. While an increasing prevalence of cannabis use disorders seem likely, the estimates of the Global Burden of Disease studies suggest the opposite. The second trend refers to an emerging market for cannabidiol (CBD) products in European countries, where regulations on CBD are lacking. Given the lack of data on users of CBD products, it can hardly be assessed if current abstainers will initiate using other cannabis products after trying CBD products for medicinal or recreational purposes. However, regulations should be implemented and enforced in order to make CBD products safer for consumers, for instance by ensuring reliable potency levels and by reducing the presence of toxic substances through quality control measures. In summary, a substantial transition of the epidemiology of cannabis use is under way, accompanied by changes in potency, treatment demand and new products. In order to assess the public health implications of this transition, data on population exposure of specific cannabinoids are required.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CBD; Cannabidiol; Cannabis; Cannabis use disorders; Drug policy; Europe; THC; Treatment

Mesh:

Substances:

Year:  2019        PMID: 31030057     DOI: 10.1016/j.drugpo.2019.03.006

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  14 in total

1.  Cannabis: An Emerging Occupational Allergen?

Authors:  Gordon L Sussman; Donald H Beezhold; John R Cohn; William S Silvers; Joanna S Zeiger; Ajay P Nayak
Journal:  Ann Work Expo Health       Date:  2020-08-06       Impact factor: 2.179

Review 2.  [Cannabis-derived medicines for the treatment of chronic pain : Problems resulting from medical appraisals in the experience of the Medical Advisory Board of the Statutory Health Insurance Funds North].

Authors:  Marc Heidbreder; Bernhard van Treeck
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

3.  A Warning against the Negligent Use of Cannabidiol in Professional and Amateur Athletes.

Authors:  Dirk W Lachenmeier; Patrick Diel
Journal:  Sports (Basel)       Date:  2019-12-14

4.  Cannabis use among Norwegian university students: Gender differences, legalization support and use intentions, risk perceptions, and use disorder.

Authors:  Jasmina Burdzovic Andreas; Børge Sivertsen; Kari Jussie Lønning; Jens Christoffer Skogen
Journal:  Addict Behav Rep       Date:  2021-01-15

5.  Use of alcohol, tobacco, cannabis, and other substances during the first wave of the SARS-CoV-2 pandemic in Europe: a survey on 36,000 European substance users.

Authors:  Jakob Manthey; Carolin Kilian; Sinclair Carr; Miroslav Bartak; Kim Bloomfield; Fleur Braddick; Antoni Gual; Maria Neufeld; Amy O'Donnell; Benjamin Petruzelka; Vladimir Rogalewicz; Ingeborg Rossow; Bernd Schulte; Jürgen Rehm
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-04-26

Review 6.  Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review.

Authors:  Ana M Martins; Ana L Gomes; Inês Vilas Boas; Joana Marto; Helena M Ribeiro
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-09

7.  Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates.

Authors:  Jakob Manthey; Tom P Freeman; Carolin Kilian; Hugo López-Pelayo; Jürgen Rehm
Journal:  Lancet Reg Health Eur       Date:  2021-09-24

8.  Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?

Authors:  Dirk W Lachenmeier; Stephanie Habel; Berit Fischer; Frauke Herbi; Yvonne Zerbe; Verena Bock; Tabata Rajcic de Rezende; Stephan G Walch; Constanze Sproll
Journal:  F1000Res       Date:  2019-08-08

9.  Time Trends in the Co-use of Cannabis and the Misuse of Tranquilizers, Sedatives and Sleeping Pills among Young Adults in Spain between 2009 and 2015.

Authors:  Domingo Palacios-Ceña; Isabel Jiménez-Trujillo; Valentín Hernández-Barrera; Lidiane Lima Florencio; Pilar Carrasco-Garrido
Journal:  Int J Environ Res Public Health       Date:  2019-09-15       Impact factor: 3.390

10.  Controlled administration of cannabis to mitigate cannabis-attributable harm among recreational users: a quasi-experimental study in Germany.

Authors:  Jakob Manthey; Jens Kalke; Jürgen Rehm; Moritz Rosenkranz; Uwe Verthein
Journal:  F1000Res       Date:  2020-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.